Low-dose decitabine as part of a modified Bu-Cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation.

摘要: Relapse is the major cause of mortality in patients with acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Effective preventive intervention high-risk AML may be crucial. In this study, we investigated clinical efficacy and safety low dose decitabine (DAC) as part a modified Busulfan-Cyclophosphamide (Bu-Cy) regimen for undergoing allo-HSCT to reduce relapse rate. Fifty-nine received DAC (20 mg/m2/d, i.v.) 5 days, followed by Bu-Cy (DAC group). A matched-pair control (CON) group 177 (matched 1:3) only. The differences were more substantial among active disease: 2-year OS, 80.7% versus 43.5% (CON), P = 0.011 LFS, 64.9% 39.2% P = 0.024. Median time was 8 months entire groups 6.5 3.5 disease. summary, our data indicated that conditioning containing confer survival advantage disease allo-HSCT, prospective randomized trial warranted confirm these observations.